Cambrex Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Cambrex's estimated annual revenue is currently $531M per year.
- Cambrex received $200.0M in venture funding in April 2007.
- Cambrex's estimated revenue per employee is $507,163
- Cambrex has 1047 Employees.
- Cambrex grew their employee count by 38% last year.
- Cambrex currently has 34 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Cambrex?
Cambrex is an innovative life sciences company with a refreshingly human approach. Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers small molecule therapeutics into markets across the world. With over 35 years of active pharmaceutical ingredient (API) development and manufacturing expertise, a growing team of more than 1,200 experts and a strong presence in the USA and Europe, we are tried and trusted across branded and generic API markets. > We put all of our energy and experience into being your partner of choice > We create value for customers through manufacturing excellence, reliable quality and innovative science > Our people are the experts that our customers enjoy working with Our custom development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. We are committed to operating our facilities with the highest standards for regulatory, environmental, health, safety, and security guidelines. We actively incorporate Lean Six Sigma to consistently deliver efficient, high quality, and cost competitive products with less time to market for our clients. We are proud of our long history of regulatory excellence. When you work with Cambrex, you can expect a friendly, energetic and customer-focused team that will deliver your project requirements. And theyll do so with passion and integrity at the core. To experience the Cambrex difference, get in touch.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Under the terms of the transaction, Cambrex shareholders will receive only $60.00 in cash each share of Cambrex stock they own.
CAMBREX INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and ...
|2004-08-03||$0.0M||Title: President CEO||Article|
|2007-04-09||$200.0M||Undisclosed||JPMorgan Chase Bank N.A||Article|
Cambrex Executive Hires
|2002-04-09||Aaron Heifetz||VP, GC & Site Dir||Article|
|2003-03-07||Gary L. Mossman||Pres Pharma Biz Unit||Article|
|2003-11-20||Gary Mossman||CEO/Pres Biopharma Biz Unit||Article|
|2005-05-10||David DeMarco||Vice President Strategic Planning||Article|
|2005-10-03||Shawn P. Cavanagh||SVP||Article|
|2005-11-08||David DeMarco||VP Strategy/Corp Dev||Article|
|2006-01-05||James A. Mack||Acting Pres/CEO||Article|
|2007-02-12||Steven M. Klosk||EVP/COO||Article|
|2008-05-16||Steven M. Klosk||President/CEO||Article|
|2008-05-16||John R. Miller||Chairman||Article|
|2015-02-03||Samantha M Hanley||VP General Counsel/Secretary||Article|
|2018-11-21||Avista Pharma Solutions||Article|
Cambrex Hiring Plans
|Date||Number of Employees||Location||Reference|